2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)
  5. Indoleamine 2,3-Dioxygenase (IDO) Isoform

Indoleamine 2,3-Dioxygenase (IDO)

 

Indoleamine 2,3-Dioxygenase (IDO) Related Products (50):

Cat. No. Product Name Effect Purity
  • HY-15760
    Necrostatin-1
    		Inhibitor 99.89%
    Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor.
  • HY-33298
    LM10
    		Inhibitor 99.91%
    LM10 is a potent inhibitor of tryptophan 2,3-dioxygenase (TDO). Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. LM10 has the potential for the research of cancer diseases.
  • HY-N0707
    (S)-Indoximod
    		Inhibitor 99.47%
    (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO) (Ki: 19 μM). (S)-Indoximod can be used for the research of cancer and neurological disease.
  • HY-144651
    IDO1-IN-18
    		Inhibitor 98.00%
    IDO1-IN-18 (Compound 14) is a potent inhibitor of IDO1. IDO1-IN-18 has the potential for the research of cancer diseases.
  • HY-N0430A
    Coptisine Sulfate
    		Inhibitor 99.37%
    Coptisine Sulfate is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM.
  • HY-162962
    IDO1/TDO-IN-7
    		Inhibitor
    IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model.
  • HY-173023
    IDOi-Pt(IV) prodrug-1
    		Inhibitor
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394).
  • HY-168092
    VS-15
    		Inhibitor
    VS-15, a IDO1 inhibitor, selectively binds the heme-free form of IDO1. VS-15 is described as an iNOS inhibitor based on the reduction of NO production.
  • HY-112164
    IACS-8968
    		Inhibitor 98.46%
    IACS-8968 (IDO/TDO Inhibitor) is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
  • HY-153764
    IDO-IN-18
    		Inhibitor
    IDO-IN-18 (Compound 00815) is an IDO inhibitor. IDO-IN-18 can be used for research of immunosuppression associated infectious or cancer diseases.
  • HY-139205
    BMT-297376
    		Inhibitor 99.14%
    BMT-297376, the optimized Linrodostat, is a potent IDO1 inhibitor.
  • HY-111540B
    (S)-LY-3381916
    		Inhibitor 99.06%
    (S)-LY-3381916 ((S)-IDO1-IN-5; Example 1B) is an active S-isomer of LY-3381916. (S)-LY-3381916 binds to IDOL with an IC50 value less than 1.5 µΜ. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
  • HY-128355
    IDO/TDO-IN-1
    		Inhibitor 99.22%
    IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively .
  • HY-111540A
    (Rac)-LY-3381916
    		Inhibitor 99.12%
    (Rac)-LY-3381916 ((Rac)-IDO1-IN-5; Example 1) is a racemate of LY-3381916. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
  • HY-115122
    IDO-IN-12
    		Inhibitor 99.22%
    IDO-IN-12 is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO 2017181849 A1.
  • HY-112164B
    IACS-8968 S-enantiomer
    		Inhibitor 98.43%
    IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
  • HY-N2463
    Kushenol E
    		Inhibitor
    Kushenol E is a class of flavonoids isolated from Sophora flavescens and is a non-competitive indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 of 7.7 µM and a Ki of 9.5 µM, has anti-tumor activity.
  • HY-151425
    TDO-IN-1
    		Inhibitor 99.07%
    TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo.
  • HY-W113615
    4-Phenyl-1H-1,2,3-triazole
    		Inhibitor ≥98.0%
    4-Phenyl-1H-1,2,3-triazole is an IDO1 inhibitor (IC50: 60 渭M). 4-Phenyl-1H-1,2,3-triazole can be used for cancer research.
  • HY-145332
    IDO1-IN-11
    		Inhibitor
    IDO1-IN-11 is an IDO1 inhibitor with an IC50 value of 0.6 nM.